強
強気
強気 · 25%PLRZ
$0.90
シナリオ価格
$11.045
-0.519 (-4.70%)終値時点
Loading chart…
- 高値
- 11.590
- 始値
- 11.590
- 出来高加重平均価格
- 11.21
- 出来高
- 7.75K
- 時価総額
- —
- 安値
- 11.000
- 売買代金
- 86.85K
- EV/EBITDA（TTM）
- 0.00
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
AI分析 of Polyrizon Ltd (PLRZ)
買いPolyrizon Ltd. is a good buy right now due to its recent clinical trial initiation for NASARIX, which targets seasonal allergic rhinitis, and a strong 1-year price increase of 110.72%. The current price of $11.05 is significantly below its 52-week high of $18.20, indicating potential for growth. However, the company has reported significant losses, with a net income of -3,158,000 USD in Q4 2025, which presents a risk.
バリュエーション指標
Polyrizon Ltd（PLRZ）の現在の予想PERは0.00で、5年平均は0.00です。
Alphio AI による PLRZ の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
イベントタイムライン
ニュース
9.010-27NewsfilterPolyrizon Completes Patient Enrollment for NASARIX Clinical Study
9.009-22NASDAQ.COMPolyrizon Initiates Clinical Trial for Seasonal Allergic Rhinitis Treatment
- 8.509-04Newsfilter
Polyrizon Closes $4 Million Financing Round
8.509-03NASDAQ.COMPolyrizon Secures $4 Million Financing Through Direct Offering and Private Placement
- 8.509-02Newsfilter
Polyrizon Completes Clinical Site Contracts for NASARIX™ Study
PLRZ のよくある質問 — Alphio AI が回答
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers.. It operates in the Healthcare sector.
Polyrizon Ltd. is a good buy right now due to its recent clinical trial initiation for NASARIX, which targets seasonal allergic rhinitis, and a strong 1-year price increase of 110.72%. The current price of $11.05 is significantly below its 52-week high of $18.20, indicating potential for growth. However, the company has reported significant losses, with a net income of -3,158,000 USD in Q4 2025, which presents a risk.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。